AbbVie’s investigational neurotoxin, designed to prevent postoperative atrial fibrillation, missed the primary endpoint in a Phase II trial, the company announced Monday.
https://www.pharmalive.com/wp-content/uploads/2021/05/AbbVie-Subsidiary-Scoops-Up-Soliton-and-Its-Cellulite-Tattoo-Removal-Device-BioSpace-5-11-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-08 10:03:232022-11-08 10:03:53AbbVie touts subgroup data in Phase II atrial fibrillation miss
